Antiarrhythmic drugs in out-of-hospital cardiac arrest: What counts and what doesn't?

Resuscitation

Volumn 109, Issue , 2016, Pages A5-A7

  Kudenchuk, Peter J ^a  

^a PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; LIDOCAINE; NIFEKALANT;

CLINICAL OUTCOME; EDITORIAL; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; META ANALYSIS (TOPIC); OUT OF HOSPITAL CARDIAC ARREST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESUSCITATION; SURVIVAL; TIME TO TREATMENT; HEART ARREST; HEART VENTRICLE FIBRILLATION;

ANTI-ARRHYTHMIA AGENTS; HEART ARREST; HUMANS; OUT-OF-HOSPITAL CARDIAC ARREST; VENTRICULAR FIBRILLATION;

EID: 84996879628     PISSN: 03009572     EISSN: 18731570     Source Type: Journal    
DOI: 10.1016/j.resuscitation.2016.09.017     Document Type: Editorial

References (14)

1. 1 Berdowski, J., ten Haaf, M., Tijssen, J.G.P., Chapman, F.W., Koster, R.W., Time in recurrent ventricular fibrillation and survival after out of hospital cardiac arrest. Circulation 122 (2010), 1101–1108.
2. 2 Olasveengen, T.M., Sunde, J., Brunborg, C., Thowsen, J., Steen, P.A., Wik, L., Intravenous drug administration during out of hospital cardiac arrest: a randomized trial. JAMA 302 (2009), 2222–2229.
3. 3 Stiell, I.G., Wells, G.A., Hebert, P.C., Laupacis, A., Weitzman, B.N., Association of drug therapy with survival in cardiac arrest: limited role of advanced cardiac life support drugs. Acad Emerg Med 2 (1995), 264–273.
4. 4 Sanfilippo, F., Corredor, C., Santonocito, C., et al. Amiodarone or lidocaine for cardiac arrest: a systematic review and meta-analysis. Resuscitation 107 (2016), 31–37.
5. 5 Ong, M.E.H., Pellis, T., Link, M.S., The use of antiarrhythmic drugs for adult cardiac arrest: a systematic review. Resuscitation 82 (2011), 665–670.
6. 6 Callaway, C.W., Epinephrine for cardiac arrest. Curr Opin Cardiol 28 (2013), 36–42.
7. 7 Saver, J.L., Fonarow, G.C., Smith, E.E., et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 309 (2013), 2480–2488.
8. 8 Larsen, M.P., Eisenberg, M.S., Cummins, R.O., Hallstrom, A.P., Predicting survival from out of hospital cardiac arrest: a graphic model. Ann Emerg Med 22 (1993), 1652–1658.
9. 9 Valenzuela, T.D., Roe, D.J., Cretin, S., Sparite, D.W., Larsen, M.S., Estimating effectiveness of cardiac arrest interventions. Circulation 96 (1997), 3308–3313.
10. 10 Sasson, C., Rogers, M.A.M., Dahl, J., Kellerman, A.L., Predictors of survival from out of hospital cardiac arrest. Circ Cardiovasc Qual Outcomes 3 (2010), 63–81.
11. 11 Kudenchuk, P.J., Brown, S.P., Daya, M., et al. Lidocaine or placebo in out-of-hospital cardiac arrest. N Engl J Med 3784 (2016), 1711–1722.
12. 12 Tagami, T., Matsui, H., Ishinokami, S., et al. Amodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest. Resuscitation 109 (2016), 127–132.
13. 13 Hallstrom, A.P., Cobb, L.A., Swain, M., Mensinger, K., Predictors of hospital mortality after out of hospital cardiopulmonary resuscitation. Crit Care Med 13 (1985), 927–929.
14. 14 Herlitz, J., Engdahl, J., Evensson, L., Angquist, K.A., Young, M., Holmberg, S., Factors associated with an increased chance of survival among patients suffering from an out of hospital cardiac arrest in a national perspective in Sweden. Am Heart J 149 (2005), 61–66.